An open-label study of Escitalopram (Lexapro®) for the treatment of 'Depression of Alzheimer's disease' (dAD)

被引：22

作者：

Rao, V ^{[1
]}

Spiro, JR ^{[1
]}

Rosenberg, PB ^{[1
]}

Lee, HB ^{[1
]}

Rosenblatt, A ^{[1
]}

Lyketsos, CG ^{[1
]}

机构：

[1] Johns Hopkins Sch Med, Dept Psychiat & Behav Sci, Div Geriatr Psychiat & Neuropsychiat, Baltimore, MD USA

来源：

INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY | 2006年 / 21卷 / 03期

关键词：

escitalopram; depression in Alzheimer's disease;

D O I：

10.1002/gps.1459

中图分类号：

R592 [老年病学]; C [社会科学总论];

学科分类号：

03 ; 0303 ; 100203 ;

摘要：

Background Depression is a frequent neuropsychiatric complication of Alzheimer's Disease. Methods This study investigated the safety and effectiveness of escitalopram (LEXAPRO) for depression in AD (dAD) as defined by the NIMH consensus criteria in an 8-week, open-label treatment study. Conclusion Escitalopram was efficacious and safe for the treatment of dAD in this study. Larger, controlled studies are warranted to further assess the efficacy for mood and behavioral disturbances in this medically fragile population. Copyright (c) 2006 John Wiley & Sons, Ltd.

引用

页码：273 / 274

页数：2

共 4 条

[1] Depression in Alzheimer's disease: Overview and treatment [J].